Checkpoint Therapeutics, Inc. is a commercial-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Its product candidates include UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic cSCC or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Additionally, the Company is engaged in evaluating its lead investigational small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 01:30:00 30/05/2025 am IST			5-day change	1st Jan Change
4.260 ^USD	+0.71%		-.--%	-

02/25/02	Checkpoint Therapeutics, Inc.(NasdaqCM:CKPT) dropped from S&P TMI Index	CI
30/25/30	Sun Pharmaceutical Industries Limited completed the acquisition of Checkpoint Therapeutics, Inc. from Fortress Biotech, Inc., Armistice Capital Master Fund Ltd., managed by Armistice Capital LLC and others.	CI

Market Cap	37Cr 33Cr 30Cr 28Cr 52Cr 3.58TCr 53Cr 360.02Cr 140.58Cr 1.75TCr 139.16Cr 136.16Cr 6.07TCr	P/E 2023	-1.23x	P/E 2024	-2.26x
Enterprise Value	36Cr 32Cr 30Cr 27Cr 51Cr 3.52TCr 52Cr 353.6Cr 138.08Cr 1.72TCr 136.68Cr 133.73Cr 5.96TCr	EV / Sales 2023	475x	EV / Sales 2024	3,650x
Free-Float	47.41%	Yield 2023 *	-	Yield 2024	-

02/25/02	Checkpoint Therapeutics, Inc.(NasdaqCM:CKPT) dropped from S&P TMI Index	CI
30/25/30	Sun Pharmaceutical Industries Limited completed the acquisition of Checkpoint Therapeutics, Inc. from Fortress Biotech, Inc., Armistice Capital Master Fund Ltd., managed by Armistice Capital LLC and others.	CI
30/25/30	Sun Pharmaceutical Industries Completes Acquisition Of Checkpoint Therapeutics	RE
30/25/30	Fortress Biotech Closes Sale of Checkpoint Therapeutics Unit	MT
30/25/30	Checkpoint Therapeutics, Inc. Appoints Zvi Albert as Chief Financial Officer	CI
30/25/30	Checkpoint Therapeutics, Inc. Announces Board and Executive Changes	CI
30/25/30	Checkpoint Therapeutics, Inc.(NasdaqGM:CKPT) dropped from NASDAQ Composite Index	CI
14/25/14	Checkpoint Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
28/25/28	Checkpoint Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
28/25/28	Checkpoint Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
11/25/11	HC Wainwright Downgrades Checkpoint Therapeutics to Neutral From Buy, $20 Price Target	MT
10/25/10	Lake Street Downgrades Checkpoint Therapeutics to Hold From Buy, $4.10 Price Target	MT
10/25/10	Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical -- Checkpoint Shares Jump Monday	MT

11/25/11	HC Wainwright Downgrades Checkpoint Therapeutics to Neutral From Buy, $20 Price Target	MT
10/25/10	Lake Street Downgrades Checkpoint Therapeutics to Hold From Buy, $4.10 Price Target	MT
20/23/20	B. Riley Lowers Checkpoint Therapeutics' Price Target to $4 From $8, Keeps Buy Rating	MT
22/23/22	B. Riley Lowers Checkpoint Therapeutics' Price Target to $8 From $15, Keeps Buy Rating	MT
15/23/15	Lake Street Adjusts Checkpoint Therapeutics Price Target to $14 From $16, Maintains Buy Rating	MT

Checkpoint Therapeutics, Inc. Share Price

Stocks

CKPT

US1628282063

Biotechnology & Medical Research

Valuation: Checkpoint Therapeutics, Inc.

Latest news : Checkpoint Therapeutics, Inc.

Analysts' recommendations: Checkpoint Therapeutics, Inc.

Press Releases: Checkpoint Therapeutics, Inc.

News in other languages: Checkpoint Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Checkpoint Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

30/25/30	Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics	AQ
14/25/14	Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates	AQ
29/25/29	CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT	BU
28/25/28	Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates	AQ
14/25/14	CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT	BU

22/24/22	Avery Dennison Corporation : Todo lo que busca
19/24/19	Zscaler, Inc.: de kunst van de Zero Trust-aanpak
17/24/17	Zscaler: l'arte dell'approccio zero trust
16/24/16	Zscaler, Inc.: El arte del enfoque de confianza cero
16/24/16	Zscaler : l'art de l'approche zero trust

Date	Insider	Type	Main position	Quantity	% Market Cap.
30/05/25	William Gray	Tender	Chief Financial Officer	14,46,322	3.0049%
30/05/25	James Oliviero	Tender	Chief Executive Officer	37,59,929	7.8116%
29/05/25	FORTRESS BIOTECH, INC.	Sell	Company	62,22,249	12.9273%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHECKPOINT THERAPEUTICS, INC.	+0.71%	-.--%	-.--%	+24.93%	36Cr
WUXI APPTEC CO., LTD.	-1.92%	-1.57%	+48.70%	+84.37%	5.59TCr
ARGENX SE	+0.93%	+7.22%	+64.67%	+63.56%	5.67TCr
BIONTECH SE	-2.97%	-2.44%	-22.05%	-17.74%	2.33TCr
INSMED INCORPORATED	-0.46%	-0.50%	+3.36%	+407.21%	2.33TCr
WUXI BIOLOGICS (CAYMAN) INC.	-0.36%	-0.56%	+36.00%	-3.93%	2.05TCr
GENMAB A/S	-1.34%	-0.63%	+29.60%	-32.53%	1.78TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.44%	-1.63%	+37.07%	+589.93%	1.59TCr
PHARMAESSENTIA CORPORATION	-1.30%	-9.92%	+160.67%	+284.37%	1.46TCr
EXELIXIS, INC.	-0.50%	-0.56%	+21.96%	+181.21%	1.4TCr
Average	-0.41%	+0.42%	+38.00%	+158.14%	2.42TCr
Weighted average by Cap.	-0.45%	+1.47%	+43.19%	+135.40%

	2023	2024
Net sales	1L 90.63T 84.22T 77.33T 1L 99.45L 1L 10L 4L 48.75L 4L 4L 1.69Cr	41T 36.08T 33.53T 30.78T 57.78T 39.59L 58.75T 4L 2L 19.4L 2L 2L 67.15L
Net income	-5.18Cr -4.56Cr -4.24Cr -3.89Cr -7.31Cr -500.59Cr -7.43Cr -50Cr -20Cr -245.39Cr -19Cr -19Cr -849.21Cr	-5.62Cr -4.95Cr -4.6Cr -4.22Cr -7.93Cr -543.01Cr -8.06Cr -55Cr -21Cr -266.18Cr -21Cr -21Cr -921.16Cr
Net Debt	-49.28L -43.36L -40.3L -37L -69.45L -48Cr -70.61L -4.79Cr -1.87Cr -23Cr -1.85Cr -1.81Cr -81Cr	-66.04L -58.11L -54L -49.58L -93.06L -64Cr -94.63L -6.41Cr -2.5Cr -31Cr -2.48Cr -2.43Cr -108.17Cr

3 years	1.3	4.5
5 years	1.3	46.4
10 years	1.3	150